Malignant hyperthermia or hyperpyrexia (Q41406): Difference between revisions

← Older edit

@@ Property / Canonical URI @@
+https://id.who.int/icd/entity/1397199211
@@ Property / Canonical URI: https://id.who.int/icd/entity/1397199211 / rank @@
+Normal rank
@@ Property / CURIE @@
+CID11:8C78
@@ Property / CURIE: CID11:8C78 / rank @@
+Normal rank
@@ Property / Canary Token @@
+dki-india-8C78
@@ Property / Canary Token: dki-india-8C78 / rank @@
+Normal rank
@@ Property / Verification Status @@
+Concluído
@@ Property / Verification Status: Concluído / rank @@
+Normal rank
@@ Property / Knowledge Architect @@
+https://pauloleads.com.br/cases-publicos/
+Normal rank
@@ Property / Collection date @@
+August 2026Timestamp +2026-08-13T00:00:00Z
Timezone +00:00
Calendar Gregorian
Precision 1 day
Before 0
After 0
-Timestamp
++2026-08-13T00:00:00Z
-Timezone
++00:00
-Calendar
+Gregorian
-Precision
+day
 Before
 After
@@ Property / Collection date: 13 August 2026 / rank @@
+Normal rank
@@ Property / Linked ICD 10 @@
+G71.8
@@ Property / Linked ICD 10: G71.8 / rank @@
+Normal rank

Latest revision as of 07:34, 13 August 2026

Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene.

Language	Label	Description	Also known as
default for all languages	8C78
English	Malignant hyperthermia or hyperpyrexia	Malignant hyperthermia is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anaesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely in humans, to stresses such as vigorous exercise and heat. May be caused by a mutation in the Ryonadine Receptor 1 gene.